Details

The trial ends when the last patient completes their last visit. The overall study objectives are to evaluate the safety and efficacy of CordIn™: single ex-vivo expanded cord blood unit transplantation in patients with hemoglobinopathies (sickle cell disease or thalassemia major) following a preparative therapy.

Keywords

Sickle Cell DiseaseThalassemiaAnemia, Sickle CellHemoglobinopathies

Eligibility

You can join if…

Open to people ages 2–25

Patient is a candidate for allogeneic SCT for treatment of SCD or thalassemia

Patients must have one partially HLA-matched CBUs

Adequate Karnofsky Performance score or Lansky Play-Performance scale

Sufficient physiological reserves

Signed written informed consent

You CAN'T join if...

Prior allogeneic HSCT

Evidence of HIV infection or HIV positive serology

Evidence of active Hepatitis B, Hepatitis C or EBV as determined by serology or PCR

Active or uncontrolled infection

Pregnancy or lactation

Locations

UCSF Benioff Children's Hospitalaccepting new patientsOakland, California, 94609, United States

Children's Nationalaccepting new patientsWashington, District of Columbia, 20010, United States